Concepedia

Author

Richard Nichols

Abcam (United States)ORCID

Also Known As

R D Nichols, R NICHOLS, R Nichols, R. D. NICHOLS, R. D. Nichols, R. Nichols, RICHARD NICHOLS, Richard D. Nichols, Richard Nichols, Rick Nichols

64

Publications

4.4K

Citations

30

H-Index

66

Concepts

All Affiliations

Abcam (United States)The University of Texas Medical Branch at GalvestonNewLink Genetics (United States)Orlando Clinical Research CenterWalter Reed Army Institute of Research
RN

About

Richard Nichols is an author at Abcam (United States) specializing in medicine, vaccine development, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

19

2.2K

2

Education

1

1

11

3

Social Sciences

1

1

17

4

Cell Biology

1

1

69

5

Epidemiology

1

1

177

Richard Nichols

×

34

Publications

3.8K

Citations

26

H-Index

YearCitations

Immunization of Mice with Urease Vaccine Affords Protection against <i>Helicobacter pylori</i> Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses

Thomas H. Ermak, Paul J. Giannasca, Richard Nichols,

The Journal of Experimental Medicine

1998

373

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori–infected adults

Pierre Michetti, Christianna Kreiss, Karen L. Kotloff,

Gastroenterology

1999

307

Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

Farshad Guirakhoo, Z. Zhang, Gene Myers,

Journal of Virology

2004

252

Reduction in Mortality in Pediatric Patients with Inhalation Injury with Aerosolized Heparin/Acetylcystine Therapy

M. Desai, Ronald P. Mlcak, J. Richardson,

Journal of Burn Care & Rehabilitation

1998

229

A live, attenuated recombinant West Nile virus vaccine

Thomas P. Monath, Jian Liu, Niranjan Kanesa-thasan,

Proceedings of the National Academy of Sciences

2006

226

Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections

Thomas P. Monath, Karen McCarthy, Philip Bedford,

Vaccine

2002

217

Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax‐JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis Antigen

Thomas P. Monath, Farshad Guirakhoo, Richard Nichols,

The Journal of Infectious Diseases

2003

216

Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All

Farshad Guirakhoo, Scott Kitchener, Dennis Morrison,

Human Vaccines

2006

191

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

Thomas P. Monath, Richard Nichols, W. Tad Archambault,

American Journal of Tropical Medicine and Hygiene

2002

177

Safety and Immunogenicity of Increasing Doses of a <i>Clostridium difficile</i> Toxoid Vaccine Administered to Healthy Adults

Karen L. Kotloff, Steven S. Wasserman, Genevieve A. Losonsky,

Infection and Immunity

2001

155

Page 1